Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin

Tao Li¹,²*, Ying Guo³*, Xianghua Zhuang¹,⁴, Laigang Huang¹,⁵, Xingqian Zhang¹,⁶, Fengtao Wei¹,⁶, Baohua Yang²
¹Medical Team Backing Hubei Province, ²Departments of Infectious Disease and Hepatology, ³Intensive Care Unit, ⁴Endocrinology, ⁵Rehabilitation Medicine, ⁶Cardiology, The Second Hospital, Cheelu College of Medicine, Shandong University, Jinan, China
*These authors contributed equally to this work

Abstract
Background/Aims: We aimed to evaluate the distribution of abnormal liver-related biomarkers in patients with coronavirus disease (COVID-19) and explore the prognostic value of elevated liver enzymes and abnormal liver synthetic capacity with regards to patient mortality.

Patients and Methods: This retrospective observational study included 80 laboratory-confirmed COVID-19 cases. Data were collected from the electronic medical record system by a trained team of physicians. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), albumin, and prealbumin levels at admission and on day 7 after admission were collected. The primary outcome of the current study was patient mortality.

Results: Abnormal ALT, AST, TB, albumin, and prealbumin levels were observed in 11 (13.8%), 15 (18.8%), 5 (6.3%), 22 (27.5%), and 31 (38.8%) patients, respectively. Male gender correlated with elevated ALT and AST levels (p = 0.027 and 0.036, respectively). Higher levels of AST and lower levels of albumin and prealbumin were associated with patient mortality (p = 0.009, 0.002, and 0.003, respectively). Multivariate Cox regression analysis identified patient age (p = 0.013, HR 1.108) and prealbumin levels (p = 0.015, HR 0.986) as independent predictors for patient mortality. However, changes in liver-related biomarkers were not associated with poor outcome in multivariate analysis (p > 0.05).

Conclusions: Abnormalities in albumin and prealbumin levels are common among COVID-19 patients and hypoprealbuminemia independently predicts adverse outcome and should be carefully considered in clinical practice. Moreover, changes in liver-related biomarkers is not a salient feature of COVID-19.

Keywords: COVID-19, hypoprealbuminemia, liver impairment, prognosis

INTRODUCTION

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to 216 countries, areas or territories, with over 7.69 million confirmed cases as of June14, 2020.¹ The lung is the main organ attacked by SARS-CoV-2. However, extrapulmonary organ injuries were also observed in patients with coronavirus disease (COVID-19).²–⁵ Liver impairment or injury has been
reported in previous studies on COVID-19; the frequency of abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in COVID-19 patients ranged from 14% to 53%.[2-7] Although liver dysfunction was shown to be more common in COVID-19 patients with severe symptoms,[6-8] several studies concluded that liver impairment may not be an independent predictor for adverse outcome of the disease.[5,8,9,10]

However, previous studies on liver impairment focused primarily on changes in ALT, AST, and total bilirubin (TB) levels. As an important biomarker for evaluating the protein synthesis function of the liver, the role of prealbumin was underappreciated and thus, not analyzed in multivariate analyses with other liver-related biomarkers.[5,8,9] Furthermore, the effects exerted by changes in liver-related biomarkers also require further clarification.

Thus, the current study systematically evaluated the effects of abnormal liver-related biomarker levels in COVID-19 patients and explored the prognostic value of elevated levels of liver enzymes and abnormal liver synthetic capacity for patient mortality.

**PATIENTS AND METHODS**

This was a retrospective observational study. Ward E1-7, Optics Valley District, Tongji Hospital Affiliated to the Tongji Medical College of HUST was a specially designated ward that was taken over by the medical team backing Hubei province from the Second Hospital of Shandong University for COVID-19 management. All patients hospitalized in the ward from February 10th to March 4th, 2020 were consecutively included. Patients were followed-up until Mar 31, 2020, on which day our medical team left Wuhan and 3 of the 80 patients were transferred to Sino-French New City Branch for further treatment.

All included patients were laboratory-confirmed cases of COVID-19, with positive results from nasal or pharyngeal swabs. The detailed procedures for nucleic acid testing are described in previously published studies. All patients admitted to the ward also presented with pneumonia, as confirmed by radiological findings. Therefore, all consecutive patients with complete data were included in the current study.

The study was approved by the Ethical Committee of the Tongji Hospital Affiliated to the Tongji Medical College of HUST and the Second Hospital of Shandong University; on April 2, 2020. The protocol also follows the Declaration of Helsinki.

The data were collected from the electronic medical record system by a trained team of physicians. The following data were collected on admission: patient age, gender, ALT, AST, TB, albumin, and prealbumin levels, white blood cell counts (WBC) and lymphocyte counts (Lym), as well as blood urea nitrogen (BUN), creatinine (Cr), D-dimer, N-terminal pro-B-type natriuretic peptide (NT-proBNP), troponin I (TnI), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) levels. Data regarding ALT, AST, TB, albumin, and prealbumin levels at day 7 after admission were also collected.

Patient mortality was designated as the primary outcome of the current study. Abnormal liver-related biomarkers were defined as ALT values of more than 40 U/L, or AST values of more than 40 U/L, or TB values of more than 17.1 μmol/L, or albumin values of less than 35 g/L, or prealbumin values of less than 200 mg/L. Risk was defined as the ratio between the biomarker levels at day 7 after admission and biomarker levels on admission.

**Statistical analyses**

Variables were presented as mean ± standard deviations, median [interquartile range (IQR)], or numbers (percentages). Moreover, the Student’s t-test, Mann-Whitney U-test, chi-square test, and Wilcoxon rank sum test were used according to the characteristics of distribution. Bivariate correlations between liver-related biomarkers and age/gender/patient mortality were analyzed using the Spearman’s Rank correlation. The Kaplan-Meier method was used to calculate differences in mortality rates between the hypoprealbuminemia group and the normal prealbumin group. Univariate and multivariate Cox regression analyses (Forward logistic regression method) were performed to investigate predictors for patient outcome. Multivariate logistic regression analysis (Forward logistic regression method) was used to indicate factors associated with hypoprealbuminemia and elevated TB levels. All statistical analyses were performed using the SPSS version 22.0 software (IBM Corp., Armonk, NY, USA).

**RESULTS**

The clinical data of the 80 hospitalized patients with COVID-19 admitted to the ward were retrospectively collected. No patients with mild disease were included in our cohort; seven patients were critical at admission and two patients progressed to be critical during follow-up. Among these patients, 9 succumbed to the disease between 7 to 40 days after admission. All other patients recovered and were discharged from the hospital (the 3 transferred patients were followed-up by colleagues of Sino-French New City Branch).
Abnormal liver-related biomarkers in COVID-19

Branch and recovered after treatment). The median age of the included patients was 62 years (IQR 50 to 68 years). Thirty-eight (47.5%) patients were male. The median follow-up time was 47 days (IQR 32 to 49 days). Comorbidities were observed in 37 patients (46.3%), including hypertension in 29 patients (36.3%), diabetes in 13 patients (16.3%), coronary heart disease in seven patients (8.8%), and respiratory diseases in three patients (3.8%). Positive HBsAg was tested in two patients, however, they were judged as HBeAg-positive chronic HBV infection or HBeAg-negative chronic HBV infection, and no therapy was needed. No chronic liver disease or cirrhosis was present. No patient developed liver failure in the present cohort. Baseline characteristics of the 80 included patients are shown in Table 1.

**Distribution of abnormal liver-related biomarkers**

Abnormal ALT, AST, TB, albumin, and prealbumin levels were observed in 11 (13.8%), 15 (18.8%), 5 (6.3%), 22 (27.5%), and 31 (38.8%) patients, respectively.

The results of the bivariate correlations revealed that older age correlated with higher levels of AST [Correlation coefficient (r) = 0.383, P < 0.001] and lower levels of albumin and prealbumin (r = -0.517, P < 0.001 and r = -0.360, P = 0.001, respectively). However, there was no significant correlation between ALT or TB levels and age (P = 0.286 and 0.651, respectively).

Bivariate correlations also revealed that elevated ALT and AST levels correlated with the male gender (r = 0.247, P = 0.027 and r = 0.234, P = 0.036, respectively). Moreover, there was no significant correlation between TB, albumin, and prealbumin levels and gender (P = 0.204, 0.579, and 0.981, respectively).

Bivariate correlations showed that platelet level was negatively correlated with albumin level (r = -0.259, P = 0.002). There was no significant correlation between ALT, AST, TB, and prealbumin levels and platelet level (r = 0.744, 0.271, 0.384, and 0.738, respectively). When patients were divided as low platelet (<200 × 10⁹/L) and high platelet (>200 × 10⁹/L) groups, no differences for mortality, age, gender, ALT, AST, TB, PA, NT-proBNP, CRP, WBC, Lym, INR and D-dimer between the two groups were found (P > 0.05), also for the albumin levels (P = 0.060).

**Table 1: Baseline characteristics of COVID-19 patients at admission**

| Characteristics          | Patients (n=80) |
|--------------------------|----------------|
| Age, years*              | 62 (50, 68)    |
| Gender, male (n, %)      | 38 (47.5%)     |
| Comorbidities (n, %)     | 37 (46.3%)     |
| WBC (10⁹/L)              | 6.31±2.04      |
| Lym (10⁹/L)              | 1.42±0.61      |
| PLT (10⁹/L)*             | 240.0 (192.5, 320.3) |
| ALT (U/L)*               | 22 (14, 33)    |
| AST (U/L)*               | 25 (15, 39)    |
| TB (umol/L)*             | 7.9 (6.6, 11.5) |
| Albumin (g/L)*           | 38.0 (34.9, 41.7) |
| Prealbumin (mg/L)*       | 211.5 (157.0, 244.8) |
| BUN (mmol/L)*            | 4.40 (3.43, 5.70) |
| Creatinine (umol/L)*     | 71.5 (53.0, 82.0) |
| INR*                     | 1.07 (1.02, 1.12) |
| D-dimer (μg/ml FEU)*     | 0.45 (0.22, 1.43) |
| NT-proBNP (pg/ml)*       | 79.5 (27.8, 199.8) |
| TnI (pg/ml)*             | 2.40 (1.90, 7.58) |
| CRP (mg/L)*              | 3.95 (0.73, 35.43) |
| Procalcitonin (ng/ml)*   | 0.06 (0.05, 0.09) |

*median (interquartile range)

Univariate Cox regression analysis also indicated that higher levels of AST and lower levels of albumin and prealbumin were predictors for patient mortality (P = 0.008, 0.003, and 0.004, respectively). Multivariate Cox regression analysis, which included age and ALT, AST, TB, albumin, and prealbumin levels, revealed that patient age (P = 0.013, HR 1.108, 95% CI 1.022-1.202) and prealbumin (P = 0.015, HR 0.986, 95% CI 0.975-0.997) were independent predictors of patient mortality [Table 2].

**Patient characteristics in relation to prealbumin levels**

The 30-day mortality rates for patients with hypoprealbuminemia and normal prealbumin levels were 19.4% and 2.0%, respectively [Figure 1]. Moreover, compared to patients with normal prealbumin levels, patients with hypoprealbuminemia were characterized by older age (P = 0.009), lower levels of Lym (P < 0.001), and higher levels of AST (P = 0.006), D-dimer (P < 0.001), NT-proBNP (P < 0.001), TnI (P < 0.001), CRP (P < 0.001), PCT (P < 0.001), and IL-6 (P < 0.001) [Table 3].

Multivariate logistic regression analysis, which included age and Lym, as well as AST, D-dimer, NT-proBNP, TnI, CRP, PCT, and IL-6 levels, revealed that lower Lym (OR 3.844, 95% CI 1.166 - 12.674, P = 0.027) and higher CRP levels (OR 0.971, 95% CI 0.948 – 0.994, P = 0.015) were independent predictors of patient mortality (P = 0.003 and 0.004, respectively).
Changes in liver-related biomarkers

The current study also collected data regarding liver-related biomarkers on day 7 after admission (75 patients). In the 9 non-survivors, there were no significant changes in ALT, AST, TB, albumin, and prealbumin levels at day 7 when compared with the biomarker values on admission. In the 66 surviving patients (5 survivors were excluded because of incomplete data at day 7), AST levels were decreased, while TB and prealbumin levels were increased at day 7 ($P = 0.004$, $0.002$, and $0.001$, respectively) [Table 4]. However, all liver-related biomarkers were not significant predictors for patient mortality in the multivariate Cox regression analysis [Table 5].

Lopinavir/ritonavir and liver-related biomarkers

The bivariate correlations showed that the use of lopinavir/ritonavir did not correlate with changes in ALT, AST, albumin, and prealbumin levels at day 7 after admission ($P = 0.291, 0.892, 0.068, and 0.319$, respectively). However, increased TB levels at day 7 was associated with the use of lopinavir/ritonavir ($r = 0.126, P = 0.041$). In the multivariate logistic regression analysis, which included age and the use of lopinavir/ritonavir, arbidol, and glucocorticoid, the drugs showed no differential odds in predicting elevated TB levels.

**DISCUSSION**

The current study demonstrated that in COVID-19 patients abnormalities in albumin and prealbumin levels may be more common than liver enzymes and TB abnormalities. Hypoprealbuminemia was shown to be an independent predictor for patient mortality, indicating the importance of the biomarker in clinical liver evaluations. On the other hand, changes in liver-related biomarkers were not predictors of adverse outcomes. This study emphasized the importance of prealbumin for outcome prediction and discussed the value of changes in liver-related biomarkers.
Table 3: Baseline characteristics of COVID-19 patients with hypoprealbuminemia and normal levels of prealbumin

| Age, years | Patients with hypoprealbuminemia (n=31) | Patients with normal prealbumin (n=49) | P* |
|---|---|---|---|
| Gender, male (n, %) | 66.0 (53.0, 70.0) | 56.0 (46.0, 66.0) | 0.009 |
| ALT (U/L) | 24.0 (15.0, 36.0) | 21.0 (13.0, 32.0) | 0.621 |
| AST (U/L) | 29.0 (20.0, 45.0) | 21.0 (14.0, 30.5) | 0.006 |
| TB (umol/L) | 8.1 (6.7, 11.4) | 7.7 (6.3, 11.6) | 0.913 |
| WBC (109/L) | 6.2±2.23 | 6.3±1.93 | 0.876 |
| Lym (109/L) | 1.04±0.49 | 1.66±0.56 | <0.001 |
| BUN (mmol/L) | 4.30 (3.60, 5.10) | 4.50 (3.55, 5.85) | 0.984 |
| Creatinine (umol/L) | 72.0 (53.0, 87.0) | 71.0 (51.5, 79.5) | 0.421 |
| INR | 1.09 (1.04, 1.17) | 1.07 (1.01, 1.10) | 0.061 |
| D-dimer (ug/ml EFU) | 1.43 (0.41, 3.41) | 0.29 (0.22, 0.93) | <0.001 |
| NT-proBNP (pg/ml) | 162.0 (63.0, 429.0) | 54.0 (23.0, 114.0) | <0.001 |
| Tnl (pg/ml) | 6.30 (2.90, 19.20) | 1.90 (1.90, 2.75) | <0.001 |
| CRP (mg/L) | 37.60 (5.80, 63.60) | 1.50 (0.55, 5.60) | <0.001 |
| Procalcitonin (ng/ml) | 0.09 (0.06, 0.16) | 0.06 (0.04, 0.06) | <0.001 |
| Interleukin-6 (pg/ml) | 11.26 (3.62, 43.62) | 2.16 (1.50, 5.16) | <0.001 |

ALT = alanine aminotransferase; AST = aspartate aminotransferase; TB = total bilirubin. *Wilcoxon rank sum test.

Table 4: Changes of liver-related biomarkers in survivors and non-survivors

| Day 0 | Day 7 | P* |
|---|---|---|
| Survivors (n=66) | | |
| ALT (U/L) | 21.0 (13.0, 33.0) | 20.0 (14.0, 33.5) | 0.303 |
| AST (U/L) | 23.5 (15.0, 33.3) | 19.0 (15.0 24.3) | 0.004 |
| TB (umol/L) | 7.7 (6.6, 11.4) | 10.5 (7.6, 14.9) | 0.002 |
| Albumin (g/L) | 38.5 (35.2, 41.7) | 38.3 (34.5, 41.6) | 0.128 |
| Prealbumin (mg/L) | 219.5 (174.8, 245.3) | 235.5 (204.8, 270.8) | 0.001 |
| Non-survivors (n=9) | | |
| ALT (U/L) | 20.0 (18.0, 36.5) | 29.0 (17.0, 53.5) | 0.374 |
| AST (U/L) | 36.0 (25.0, 60.5) | 33.0 (27.0, 54.0) | 0.441 |
| TB (umol/L) | 9.8 (7.3, 13.4) | 14.2 (10.1, 23.5) | 0.123 |
| Albumin (g/L) | 32.5 (30.6, 36.7) | 30.8 (24.7, 37.0) | 0.173 |
| Prealbumin (mg/L) | 96.0 (82.5, 163.0) | 105.0 (80.0, 153.0) | 0.672 |

ALT = alanine aminotransferase; AST = aspartate aminotransferase; TB = total bilirubin. *Wilcoxon rank sum test. †median (interquartile range).
of liver enzymes or gender differences in COVID-19 evolution requires further investigation. We also found that older age was correlated with higher AST levels and lower albumin and prealbumin levels. Feng et al. hypothesized that older age correlates with a higher risk of liver impairment, considering the absence of liver damage in children with COVID-19.\(^\text{[19]}\) However, Xie et al. found no significant differences in age between patients with and without liver injury.\(^\text{[8]}\) Consistent with previous studies, the results of the current study showed that age was an independent predictor of poor patient outcomes.\(^\text{[3,20,21]}\) Elderly patients tend to be associated with a decline in immune response\(^\text{[22]}\) and relatively poor nutritional status, which then leads to a poor prognosis.

Reduced platelet levels were observed in patients with cirrhosis; however, inflammatory cytokines may induce the release of platelets from megakaryocytes.\(^\text{[23]}\) The negative correlation between platelet and albumin may be due to the influence of inflammation. However, in view of the lack of difference found in albumin levels between low platelet (<200 × 10\(^9\)/L) and high platelet (>200 × 10\(^9\)/L) groups, the clinical value of this negative correlation should be further evaluated.

This study has several limitations. First, this was a retrospective study and the presence of bias cannot be excluded. Second, only a few patients in our cohort had a pre-existing liver disease and, therefore, it was difficult to evaluate the influence of liver-related comorbidities. Third, although the present study might be the first to explore the predictive value of changes in liver-related biomarkers using multivariate analysis, we only discussed changes exhibited in the first week after admission due to the limited survival time in several cases. Thus, further evaluation of the changes in liver-related biomarkers in COVID-19 patients should provide helpful insight for clinicians.

In conclusion, elevated levels of liver enzymes and TB were not rare in patients with COVID-19. However, abnormalities in albumin and prealbumin levels were found to be more common in this patient population. Hypoprealbuminemia was also shown to independently predict adverse outcome and should, therefore, be evaluated and monitored in clinical practice. Moreover, changes in liver-related biomarkers might not be salient characteristics of COVID-19.

Acknowledgments
The authors thank all members of medical team backing Hubei province from the Second Hospital of Shandong University. The authors also thank colleagues of the Second Hospital of Shandong University and Tongji Hospital who continue to work in their station and give us great support.

We would also like to thank Editage (www.editage.cn) for English language editing.

Financial support and sponsorship
This study was funded by Shandong Province Natural Science Foundation (No. ZR2019PH 052).

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. WHO. Coronavirus disease (COVID-19) outbreak situation [cited 2020 Jun 15]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020;368:m1091.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;95:1054-62.
6. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int 2020;40:1278-81.
7. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: Management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.
8. Xie H, Zhao J, Lian N, Su L, Xie Q, Zhao H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int 2020;40:1321-6.
9. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020; doi: 10.1111/liv.14455.
10. Bangash MN, Patel J, Parikh D. COVID-19 and the liver: Little cause for concern. Lancet Gastroenterol Hepatol 2020;5:529-30.
11. Cai Q, Huang D, Yu H, Chen J, Liu L, Xu L. Characteristics of liver tests in COVID-19 patients. J Hepatol 2020;73:566-74.
12. Guan GW, Gao L, Wang JW, Wen XJ, Mao TH, Peng SW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi 2020;28:100-6.

Li, et al.: Abnormal liver-related biomarkers in COVID-19

| Table 5: Univariate and multivariate Cox analyses revealing predictive value of R biomarker for patient death |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Univariate analysis | Multivariate analysis |
| | HR (95%CI) | P | HR (95%CI) | P |
| Age | 1.101 (1.032, 1.174) | 0.003 | 1.101 (1.032, 1.174) | 0.003 |
| R\(_{\text{ALT}}\)* | 1.936 (0.519, 7.221) | 0.325 | 1.101 (1.032, 1.174) | 0.325 |
| R\(_{\text{AST}}\)* | 1.061 (2.256, 4.247) | 0.934 | 1.101 (1.032, 1.174) | 0.934 |
| R\(_{\text{TB}}\)* | 1.720 (0.357, 8.287) | 0.499 | 1.101 (1.032, 1.174) | 0.499 |
| R\(_{\text{albumin}}\)* | 1.627 (0.437, 6.063) | 0.466 | 1.101 (1.032, 1.174) | 0.466 |
| R\(_{\text{prealbumin}}\)* | 0.437 (0.117, 1.633) | 0.219 | 1.101 (1.032, 1.174) | 0.219 |

ALT=alanine aminotransferase; AST=aspartate aminotransferase; TB=total bilirubin. R\(_{\text{biomarker}}\)=biomarker at day 7/biomarker at admission. *≥1 vs. ≤1
13. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
14. Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. J Clin Invest 2020;130:2202-5.
15. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet 2018;392:75-87.
16. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-99.
17. Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and clinical outcomes: What is the mechanism behind the relationship? Am Surg 2017;83:1220-7.
18. Smith SH. Using albumin and prealbumin to assess nutritional status. Nursing 2017;47:65-6.
19. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8:18-24.
20. Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J 2020;133:1032-8.
21. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43.
22. Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. Naive T cell maintenance and function in human aging. J Immunol 2015;194:4073-80.
23. Couldwell G, Machlus KR. Modulation of megakaryopoiesis and platelet production during inflammation. Thromb Res 2019;179:114-20.